Shanghai-based biopharma firm EpimAb Biotherapeutics has closed a $25-million Series A round led by Oriza Seed Venture Capital, backed by Chinese management fund Oriza Holdings.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
